# A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct05440708/  
OnCo record `nct05440708` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Tvardi Therapeutics, Incorporated, now recruiting.

## Summary

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT05440708 by Tvardi Therapeutics, Incorporated, with 193 participants planned, started 2023-03-23 and due to reach its primary completion in 2027-02-01. Interventions recorded: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05440708
- Phase: 1/2
- Setting: REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Sponsor: Tvardi Therapeutics, Incorporated
- Enrolled: 193

## Sources

- ClinicalTrials.gov NCT05440708: https://clinicaltrials.gov/study/NCT05440708

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05440708.json